{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:51:45Z","timestamp":1789030305452,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.urology.2025.08.013","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:35:40Z","timestamp":1755012940000},"page":"76-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Muscle-Invasive Bladder Cancer Treatment Selection in an Emerging Treatment Era: A Patient Preference Study"],"prefix":"10.1016","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-9817","authenticated-orcid":false,"given":"Angela B.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Chisolm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Squires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Vass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2025.08.013_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2025.08.013_bib2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.08.013_bib3","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urology.2025.08.013_bib4","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","article-title":"Updated 2016 EAU Guidelines on muscle-invasive and metastatic bladder cancer","volume":"71","author":"Alfred Witjes","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2025.08.013_bib5","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"39","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2025.08.013_bib6","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","author":"Apolo","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2025.08.013_bib7","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2025.08.013_bib8","unstructured":"ClinicalTrials.gov. NCT03661320: A study to compare chemotherapy alone versus chemotherapy plus nivolumab or nivolumab and BMS-986205, followed by continued therapy after surgery with nivolumab or nivolumab and BMS-986205 in participants with muscle invasive bladder cancer. 2024. \u3008https:\/\/www.clinicaltrials.gov\/study\/NCT03661320\u3009."},{"key":"10.1016\/j.urology.2025.08.013_bib9","unstructured":"ClinicalTrials.gov. NCT03732677: Durvalumab+ gemcitabine\/cisplatin (neoadjuvant treatment) and durvalumab (adjuvant treatment) in patients with MIBC (NIAGARA). 2024. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03732677\u3009."},{"key":"10.1016\/j.urology.2025.08.013_bib10","unstructured":"ClinicalTrials.gov. NCT03924895: Perioperative pembrolizumab (MK-3475) plus cystectomy or perioperative pembrolizumab plus enfortumab vedotin plus cystectomy versus cystectomy alone in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MK-3475\u2013905\/KEYNOTE-905\/EV-303). 2024. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03924895\u3009."},{"key":"10.1016\/j.urology.2025.08.013_bib11","unstructured":"ClinicalTrials.gov. NCT04700124: Perioperative enfortumab vedotin (EV) plus pembrolizumab (MK-3475) versus neoadjuvant chemotherapy for cisplatin-eligible muscle invasive bladder cancer (MIBC) (MK-3475-B15\/ KEYNOTE-B15\/EV-304) (KEYNOTE-B15). 2024. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04700124\u3009."},{"key":"10.1016\/j.urology.2025.08.013_bib12","unstructured":"ClinicalTrials.gov. NCT03924856: Perioperative pembrolizumab (MK-3475) plus neoadjuvant chemotherapy versus perioperative placebo plus neoadjuvant chemotherapy for cisplatin-eligible muscle-invasive bladder cancer (MIBC) (MK-3475\u2013866\/KEYNOTE-866) (KEYNOTE-866). 2024. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03924856\u3009."},{"key":"10.1016\/j.urology.2025.08.013_bib13","unstructured":"ClinicalTrials.gov. NCT04960709: Treatment combination of durvalumab, tremelimumab and enfortumab vedotin or durvalumab and enfortumab vedotin in patients with muscle invasive bladder cancer ineligible to cisplatin or who refuse cisplatin (VOLGA). 2024. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04960709\u3009."},{"key":"10.1016\/j.urology.2025.08.013_bib14","unstructured":"ClinicalTrials.gov. NCT04660344: A study of atezolizumab versus placebo as adjuvant therapy in patients with high-risk muscle-invasive bladder cancer who are ctDNA positive following cystectomy (IMvigor011). 2024. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04660344\u3009."},{"key":"10.1016\/j.urology.2025.08.013_bib15","unstructured":"ClinicalTrials.gov. NCT03244384: Testing MK-3475 (pembrolizumab) after surgery for localized muscle-invasive bladder cancer and locally advanced urothelial cancer (AMBASSADOR). 2024. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03244384\u3009."},{"key":"10.1016\/j.urology.2025.08.013_bib16","unstructured":"ClinicalTrials.gov. NCT04241185: Efficacy and safety of pembrolizumab (MK-3475) in combination with chemoradiotherapy (CRT) versus CRT alone in muscle-invasive bladder cancer (MIBC) (MK-3475\u2013992\/KEYNOTE-992). 2024. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04241185\u3009."},{"key":"10.1016\/j.urology.2025.08.013_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.urolonc.2020.09.032","article-title":"Predicting morbidity and mortality after radical cystectomy using risk calculators: a\u00a0comprehensive review of the literature","volume":"39","author":"Razdan","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2025.08.013_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043266","article-title":"Short-term morbidity and mortality following radical cystectomy: a systematic review","volume":"11","author":"Maibom","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.urology.2025.08.013_bib19","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.21037\/tau.2020.02.01","article-title":"Health-related quality of life after radical cystectomy","volume":"9","author":"Choi","year":"2020","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urology.2025.08.013_bib20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.urology.2025.08.013_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","article-title":"Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force","volume":"16","author":"Reed Johnson","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.urology.2025.08.013_bib22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health--a checklist: a report of the ISPOR good research practices for conjoint analysis task force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.urology.2025.08.013_bib23","first-page":"31","article-title":"Using the threshold technique to elicit patient preferences: an introduction to the method and an overview of existing empirical applications","volume":"18","author":"Hauber","year":"2020","journal-title":"Appl\u00a0Health Econ\u00a0Health Policy"},{"key":"10.1016\/j.urology.2025.08.013_bib24","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2217\/fon-2021-0273","article-title":"Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: phase III KEYNOTE-866 and KEYNOTE-905\/EV-303","volume":"17","author":"Galsky","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.urology.2025.08.013_bib25","first-page":"v401","article-title":"KEYNOTE-866: phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC)","volume":"30","author":"Siefker-Radtke","year":"2019","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.urology.2025.08.013_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijchp.2017.12.001","article-title":"Psychometric properties of the shared decision-making questionnaire (SDM-Q-9) in oncology practice","volume":"18","author":"Calderon","year":"2018","journal-title":"Int J Clin Health Psychol"},{"key":"10.1016\/j.urology.2025.08.013_bib27","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/cncr.31530","article-title":"Patient-centered prioritization of bladder cancer research","volume":"124","author":"Smith","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2025.08.013_bib28","doi-asserted-by":"crossref","unstructured":"NCI. Surveillance, Epidemiology, and End Results (SEER) program. 2024.","DOI":"10.1093\/jncimonographs\/lgae033"},{"key":"10.1016\/j.urology.2025.08.013_bib29","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/bco2.443","article-title":"Treatment preferences of patients with muscle invasive bladder cancer: a\u00a0discrete choice experiment","volume":"5","author":"Mannion","year":"2024","journal-title":"BJUI Compass"},{"key":"10.1016\/j.urology.2025.08.013_bib30","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.2147\/PPA.S411751","article-title":"Patient preferences for adjuvant treatment in muscle-invasive urothelial carcinoma: a multi-country discrete choice experiment","volume":"17","author":"King-Concialdi","year":"2023","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.urology.2025.08.013_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2019.112736","article-title":"Can healthcare choice be predicted using stated preference data?","volume":"246","author":"de Bekker-Grob","year":"2020","journal-title":"Soc Sci Med"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525007678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525007678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:44:30Z","timestamp":1772829870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429525007678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"alternative-id":["S0090429525007678"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2025.08.013","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Muscle-Invasive Bladder Cancer Treatment Selection in an Emerging Treatment Era: A Patient Preference Study","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2025.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates and The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}